2415. Deputy Ken O'Flynn asked the Minister for Health the number of pharmacy reimbursement claims submitted, approved, adjusted, rejected and successfully appealed in each year from 2020 to date, together with the most common reasons recorded for claim rejection or adjustment. [44053/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Ken O'Flynn under the heading Medicinal Products.
196 questions match, newest first.
2416. Deputy Ken O'Flynn asked the Minister for Health whether any internal audit, external audit, assurance review, risk assessment or value-for-money review of PCRS reimbursement decision-making processes, claim validation controls, claim rejection procedures or reference pricing arrangements has been completed since 2020 and to provide the dates and findings of such reviews. [44054/26]
1111. Deputy Ken O'Flynn asked the Minister for Health whether her Department or the HSE has carried out any national assessment since 2020 of the annual cost to the Exchequer of unused, expired, uncollected, or otherwise wasted medicines under State-funded medicine schemes; and if she will publish any such assessment. [38763/26]
1112. Deputy Ken O'Flynn asked the Minister for Health whether the HSE records the quantity and estimated value of unused or expired medicines returned to community pharmacies under State-funded medicine schemes; and if not, whether she intends to establish such a reporting mechanism. [38764/26]
1113. Deputy Ken O'Flynn asked the Minister for Health what policy measures are currently in place to reduce avoidable medicines waste under the GMS, DPS, LTI and other community drug schemes. [38765/26]
1114. Deputy Ken O'Flynn asked the Minister for Health whether his Department has examined the role of repeat prescribing, automatic renewals, phased dispensing, blister-pack changes, and non-adherence in contributing to medicines waste; and whether any reform proposals are under consideration. [38766/26]
1115. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has a national medicines waste reduction strategy; and if not, whether one will be developed in light of recent research estimating annual medicines waste at over €37.5 million. [38767/26]
1116. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has estimated the environmental impact of unused or expired medicines, including disposal, incineration, contamination risk, and pharmaceutical residues entering water systems. [38768/26]
1117. Deputy Ken O'Flynn asked the Minister for Health when the proposed national scheme for safe disposal of unused medicines will be introduced; what funding has been allocated; whether it will involve community pharmacies; and whether it will operate nationally. [38769/26]
1118. Deputy Ken O'Flynn asked the Minister for Health whether the HSE reimburses medicines which are dispensed but never collected by patients; what safeguards exist to prevent unnecessary reimbursement; and whether data on uncollected medicines is centrally collected. [38770/26]
1119. Deputy Ken O'Flynn asked the Minister for Health whether medication reviews for patients on multiple prescriptions are being used systematically to reduce over-prescribing, duplication, and avoidable waste; and what targets or KPIs apply. [38771/26]
1120. Deputy Ken O'Flynn asked the Minister for Health whether his Department has assessed potential savings from reducing medicines waste by 10%, 20% or 30%; and whether such savings have been modelled for reinvestment in frontline pharmacy or prescribing services. [38772/26]
1134. Deputy Ken O'Flynn asked the Minister for Health the division of the HSE or Department of Health that holds responsibility for estimating the number of patients clinically eligible for orphan medicinal products approved for reimbursement in the State (details supplied). [38846/26]
1135. Deputy Ken O'Flynn asked the Minister for Health if any budget impact assessment, cost projection, prevalence estimate, or epidemiological model was prepared in advance of reimbursement consideration for omaveloxolone (skyclarys); and the details of same. [38847/26]
1137. Deputy Ken O'Flynn asked the Minister for Health how reimbursement decisions for high-cost orphan medicines are financially planned where the HSE does not centrally retain data regarding the number of clinically eligible patients. [38849/26]
1138. Deputy Ken O'Flynn asked the Minister for Health if the National Centre for Pharmacoeconomics, the HSE medicines management programme, or any external body estimated the likely eligible patient cohort for omaveloxolone (skyclarys) prior to reimbursement consideration. [38850/26]
1139. Deputy Ken O'Flynn asked the Minister for Health if any hospitals, hospital groups, or specialist neurology centres currently facilitate access to omaveloxolone (skyclarys) through named-patient arrangements, manufacturer-supported supply, or exceptional approval mechanisms outside PCRS reimbursement pathways. [38854/26]
1140. Deputy Ken O'Flynn asked the Minister for Health if the HSE maintains any national policy governing interim patient access to medicines awaiting reimbursement decisions for rare diseases. [38855/26]
1141. Deputy Ken O'Flynn asked the Minister for Health if the Department or HSE has examined establishing a formal compassionate or early-access medicines framework for patients with rare progressive conditions pending health technology assistant and reimbursement determinations. [38856/26]
1142. Deputy Ken O'Flynn asked the Minister for Health the number of reimbursement applications for orphan or ultra-orphan medicines remain under assessment by the HSE for more than 12 months as of May 2026. [38857/26]
1143. Deputy Ken O'Flynn asked the Minister for Health if the HSE records the number of patients who seek access to medicines through named-patient or exceptional approval mechanisms outside standard reimbursement arrangements. [38858/26]
1225. Deputy Ken O'Flynn asked the Minister for Health if her Department or HSE has considered establishing an accelerated reimbursement pathway for medicines relating to rare progressive neurological disorders. [39070/26]
1226. Deputy Ken O'Flynn asked the Minister for Health the average duration of the pricing and reimbursement process for orphan medicines since 2020, from initial application to final decision. [39071/26]
1227. Deputy Ken O'Flynn asked the Minister for Health if a review has been undertaken into the patient impact of delays in reimbursement decisions for orphan or rare disease medicines. [39072/26]
1230. Deputy Ken O'Flynn asked the Minister for Health if there is a mechanism permitting interim or conditional reimbursement for medicines treating progressive neurological diseases pending completion of the full reimbursement process. [39075/26]